Bone Fracture - Pipeline Review, H1 2018
Bone Fracture - Pipeline Review, H1 2018
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Fracture - Pipeline Review, H1 2018, provides an overview of the Bone Fracture (Musculoskeletal Disorders) pipeline landscape.
Fractures are simply a break in a bone caused by forces that exceed the strength of the osseous tissue in the bone. Signs and symptoms of a fracture include swelling or bruising over a bone, deformity of an arm or leg, loss of function in the injured area and in compound fractures, bone protruding from the skin.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Fracture - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bone Fracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 7, 1, 12 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.
Bone Fracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Fracture - Pipeline Review, H1 2018, provides an overview of the Bone Fracture (Musculoskeletal Disorders) pipeline landscape.
Fractures are simply a break in a bone caused by forces that exceed the strength of the osseous tissue in the bone. Signs and symptoms of a fracture include swelling or bruising over a bone, deformity of an arm or leg, loss of function in the injured area and in compound fractures, bone protruding from the skin.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Fracture - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bone Fracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 7, 1, 12 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.
Bone Fracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Fracture (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bone Fracture (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bone Fracture (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bone Fracture (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bone Fracture (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Bone Fracture - Overview
Bone Fracture - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bone Fracture - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bone Fracture - Companies Involved in Therapeutics Development
American Gene Technologies International Inc
BiologicsMD Inc
Biopharm GmbH
Bone Therapeutics SA
Cellmid Ltd
Chrysalis BioTherapeutics Inc
Entera Bio Ltd
Escape Therapeutics Inc
ethris GmbH
Hemostemix Inc
Kuros Biosciences AG
Laboratorios SALVAT SA
Novartis AG
Pluristem Therapeutics Inc
TissueGene Inc
Viking Therapeutics Inc
Bone Fracture - Drug Profiles
ALLOB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMD-1221 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyndacel-M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate BMP2 and VEGF for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HCSVT-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAL-436 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAL-439 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KUR-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KUR-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Midkine for Bone Fractures - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Activate BMP-2 for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OsteoStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-PAD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Agonize PTH1R for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rusalatide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-008399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-5211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bone Fracture - Dormant Projects
Bone Fracture - Discontinued Products
Bone Fracture - Product Development Milestones
Featured News & Press Releases
Feb 19, 2018: Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB
Dec 12, 2017: Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israel’s Ministry of Health, Supporting Pivotal-Stage Studies
Nov 28, 2017: Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Nov 22, 2017: Pluristem Granted Key U.S. Patent for Skeletal Muscle Regeneration - a Meaningful Asset Ahead of Upcoming Phase III Femoral Neck Fracture Study
Oct 02, 2017: $7.9 Million Granted to nTRACK Collaborative Project Designed to Study Pluristem’s PLX-PAD Cells
Sep 26, 2017: Pluristem Receives Positive Feedback from FDA and EMA as Company Prepares for Phase III Trial of PLX-PAD to Support Recovery from Hip Fracture
Sep 25, 2017: Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings
Sep 20, 2017: Bone Therapeutics: announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis
Sep 14, 2017: Bone Therapeutics: Reports strong interim results from ALLOB Phase IIA spinal fusion study
Sep 05, 2017: Pluristem Therapeutics: $8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program
Jul 12, 2017: Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study
Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
Sep 01, 2016: Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016
Aug 09, 2016: Cellmid: New Publication For Cellmid Midkine Antibody
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Bone Fracture - Overview
Bone Fracture - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bone Fracture - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bone Fracture - Companies Involved in Therapeutics Development
American Gene Technologies International Inc
BiologicsMD Inc
Biopharm GmbH
Bone Therapeutics SA
Cellmid Ltd
Chrysalis BioTherapeutics Inc
Entera Bio Ltd
Escape Therapeutics Inc
ethris GmbH
Hemostemix Inc
Kuros Biosciences AG
Laboratorios SALVAT SA
Novartis AG
Pluristem Therapeutics Inc
TissueGene Inc
Viking Therapeutics Inc
Bone Fracture - Drug Profiles
ALLOB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMD-1221 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyndacel-M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate BMP2 and VEGF for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HCSVT-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAL-436 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAL-439 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KUR-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KUR-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Midkine for Bone Fractures - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Activate BMP-2 for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OsteoStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-PAD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Agonize PTH1R for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rusalatide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-008399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-5211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bone Fracture - Dormant Projects
Bone Fracture - Discontinued Products
Bone Fracture - Product Development Milestones
Featured News & Press Releases
Feb 19, 2018: Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB
Dec 12, 2017: Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israel’s Ministry of Health, Supporting Pivotal-Stage Studies
Nov 28, 2017: Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Nov 22, 2017: Pluristem Granted Key U.S. Patent for Skeletal Muscle Regeneration - a Meaningful Asset Ahead of Upcoming Phase III Femoral Neck Fracture Study
Oct 02, 2017: $7.9 Million Granted to nTRACK Collaborative Project Designed to Study Pluristem’s PLX-PAD Cells
Sep 26, 2017: Pluristem Receives Positive Feedback from FDA and EMA as Company Prepares for Phase III Trial of PLX-PAD to Support Recovery from Hip Fracture
Sep 25, 2017: Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings
Sep 20, 2017: Bone Therapeutics: announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis
Sep 14, 2017: Bone Therapeutics: Reports strong interim results from ALLOB Phase IIA spinal fusion study
Sep 05, 2017: Pluristem Therapeutics: $8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program
Jul 12, 2017: Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study
Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
Sep 01, 2016: Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016
Aug 09, 2016: Cellmid: New Publication For Cellmid Midkine Antibody
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Bone Fracture, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Bone Fracture - Pipeline by American Gene Technologies International Inc, H1 2018
Bone Fracture - Pipeline by BiologicsMD Inc, H1 2018
Bone Fracture - Pipeline by Biopharm GmbH, H1 2018
Bone Fracture - Pipeline by Bone Therapeutics SA, H1 2018
Bone Fracture - Pipeline by Cellmid Ltd, H1 2018
Bone Fracture - Pipeline by Chrysalis BioTherapeutics Inc, H1 2018
Bone Fracture - Pipeline by Entera Bio Ltd, H1 2018
Bone Fracture - Pipeline by Escape Therapeutics Inc, H1 2018
Bone Fracture - Pipeline by ethris GmbH, H1 2018
Bone Fracture - Pipeline by Hemostemix Inc, H1 2018
Bone Fracture - Pipeline by Kuros Biosciences AG, H1 2018
Bone Fracture - Pipeline by Laboratorios SALVAT SA, H1 2018
Bone Fracture - Pipeline by Novartis AG, H1 2018
Bone Fracture - Pipeline by Pluristem Therapeutics Inc, H1 2018
Bone Fracture - Pipeline by TissueGene Inc, H1 2018
Bone Fracture - Pipeline by Viking Therapeutics Inc, H1 2018
Bone Fracture - Dormant Projects, H1 2018
Bone Fracture - Dormant Projects, H1 2018 (Contd..1), H1 2018
Bone Fracture - Discontinued Products, H1 2018
Number of Products under Development for Bone Fracture, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Bone Fracture - Pipeline by American Gene Technologies International Inc, H1 2018
Bone Fracture - Pipeline by BiologicsMD Inc, H1 2018
Bone Fracture - Pipeline by Biopharm GmbH, H1 2018
Bone Fracture - Pipeline by Bone Therapeutics SA, H1 2018
Bone Fracture - Pipeline by Cellmid Ltd, H1 2018
Bone Fracture - Pipeline by Chrysalis BioTherapeutics Inc, H1 2018
Bone Fracture - Pipeline by Entera Bio Ltd, H1 2018
Bone Fracture - Pipeline by Escape Therapeutics Inc, H1 2018
Bone Fracture - Pipeline by ethris GmbH, H1 2018
Bone Fracture - Pipeline by Hemostemix Inc, H1 2018
Bone Fracture - Pipeline by Kuros Biosciences AG, H1 2018
Bone Fracture - Pipeline by Laboratorios SALVAT SA, H1 2018
Bone Fracture - Pipeline by Novartis AG, H1 2018
Bone Fracture - Pipeline by Pluristem Therapeutics Inc, H1 2018
Bone Fracture - Pipeline by TissueGene Inc, H1 2018
Bone Fracture - Pipeline by Viking Therapeutics Inc, H1 2018
Bone Fracture - Dormant Projects, H1 2018
Bone Fracture - Dormant Projects, H1 2018 (Contd..1), H1 2018
Bone Fracture - Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development for Bone Fracture, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
COMPANIES MENTIONED
American Gene Technologies International Inc
BiologicsMD Inc
Biopharm GmbH
Bone Therapeutics SA
Cellmid Ltd
Chrysalis BioTherapeutics Inc
Entera Bio Ltd
Escape Therapeutics Inc
ethris GmbH
Hemostemix Inc
Kuros Biosciences AG
Laboratorios SALVAT SA
Novartis AG
Pluristem Therapeutics Inc
TissueGene Inc
Viking Therapeutics Inc
Number of Products under Development for Bone Fracture, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
COMPANIES MENTIONED
American Gene Technologies International Inc
BiologicsMD Inc
Biopharm GmbH
Bone Therapeutics SA
Cellmid Ltd
Chrysalis BioTherapeutics Inc
Entera Bio Ltd
Escape Therapeutics Inc
ethris GmbH
Hemostemix Inc
Kuros Biosciences AG
Laboratorios SALVAT SA
Novartis AG
Pluristem Therapeutics Inc
TissueGene Inc
Viking Therapeutics Inc
